Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CTSE | P14091 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109118 | 0.97 | CCR5 (0.37) | CCR5TACR1USP2SMN1; SMN2KDM4E | |
| SCHEMBL4130653 | 0.87 | CCR5 (0.39) | CCR5TACR1USP2SMN1; SMN2KDM4E | |
| SCHEMBL7015877 | 0.83 | TACR1 (0.38) | TACR1 | |
| SCHEMBL18940727 | 0.81 | ENPP2 (0.42) | CCR5TACR1KDM4EMAPTTHRB | |
| SCHEMBL17140401 | 0.79 | ENPP2 (0.37) | CCR5TACR1KDM4EMAPTTHRB | |
| SCHEMBL17140769 | 0.77 | BACE1 (0.36) | CCR5TACR1KDM4EMAPTTHRB | |
| SCHEMBL7016393 | 0.75 | MEN1 (0.44) | SMN1; SMN2GPR119 | |
| SCHEMBL6087981 | 0.74 | USP2 (0.40) | CCR5TACR1USP2SMN1; SMN2KDM4E | |
| SCHEMBL4137608 | 0.73 | USP2 (0.39) | CCR5TACR1USP2SMN1; SMN2KDM4E | |
| SCHEMBL17140990 | 0.72 | CCR5 (0.49) | CCR5TACR1NPC1L1GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | CCR5 3438/4885TACR1 1484/4885USP2 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.